1. Home
  2. ROL vs INSM Comparison

ROL vs INSM Comparison

Compare ROL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rollins Inc.

ROL

Rollins Inc.

HOLD

Current Price

$53.74

Market Cap

26.5B

Sector

Finance

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$143.94

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROL
INSM
Founded
1948
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5B
30.1B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
ROL
INSM
Price
$53.74
$143.94
Analyst Decision
Buy
Strong Buy
Analyst Count
10
24
Target Price
$66.10
$190.43
AVG Volume (30 Days)
2.5M
1.8M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
1.37%
N/A
EPS Growth
13.54
N/A
EPS
1.09
N/A
Revenue
$2,161,220,000.00
N/A
Revenue This Year
$10.42
$168.46
Revenue Next Year
$8.81
$65.97
P/E Ratio
$48.78
N/A
Revenue Growth
7.23
N/A
52 Week Low
$51.77
$60.40
52 Week High
$66.14
$212.75

Technical Indicators

Market Signals
Indicator
ROL
INSM
Relative Strength Index (RSI) 30.87 46.70
Support Level N/A $142.99
Resistance Level $58.38 $149.08
Average True Range (ATR) 1.31 4.54
MACD -0.30 0.42
Stochastic Oscillator 11.72 57.57

Price Performance

Historical Comparison
ROL
INSM

About ROL Rollins Inc.

Rollins is a global leader in route-based pest control services, with operations primarily in the United States and across North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US and Canada, with near-national coverage. It also has a portfolio of other brands, which it uses to reach customers through alternative sales channels. Residential pest and termite prevention accounts for the majority of Rollins' services, reflecting its ongoing focus on the US and Canadian markets.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: